While many celebrated the FDA approval of Descovy for PrEP earlier this month, advocates wonder whether it will make biomedical HIV prevention more or less accessible to those most in need.
While 2-1-1 or "on-demand" pre-exposure prophylaxis (PrEP) has been approved by major public health agencies, doctors still face uncertainty in implementing it.
"We realized that if we still wanted to have this vision of ending the epidemic here, we need to address health care inequities in the LGBTQ community."
"Yes, the numbers are going down, but don't get too excited."
In a sign of growing frustration with the rollout of the federal Ending the HIV Epidemic plan, dozens of activists stormed the U.S. Conference on AIDS (USCA) opening plenary session on Sept. 5.
Experts agree: Your health is important enough to ask for protection, and it might be part of your journey to empowerment.
But is the U.S. ready to embrace it?
Knowing your status, and having the current information on treatment and care, is everyone's business, Toraje Heyward writes.
NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
Racism and Homophobia in Health Care Settings May Reduce PrEP Uptake for Young Black Gay and Bisexual Men, Study Finds
Racial segregation and medical mistrust in Milwaukee may keep pre-exposure prophylaxis out of their hands.